LONDON, May 12 -- The government of the United Kingdom issued the following news:

* Isomorphic Labs-a company usingfrontierAI for drug design and development- isthelatestto receiveinvestmentfrom Sovereign AI. * Investment forms part of araise by London-basedscale-upas Britain's AI sector continues to accelerate. * Isomorphic Labs is founded by AI pioneer Sir Demis Hassabis, whose breakthroughs have been honoured with accolades including the Nobel Prize and Breakthrough Prize.

Isomorphic Labs,aLondon-founded and headquarteredcompany,usingAI to design and developnew medicines, has been named as the latest firm to receive investment from the UK Government's Sovereign AI Fund today (Tuesday 12 May).

The investment forms part of a fundraise announced by Isomorphic Labstoday,asitscales up its work to tackle some of the world's most serious diseases.

The company, founded by Nobel Prize-winner Sir Demis Hassabis, isreimaginingdrug discovery, withAIat its core.

Launched just last month,Sovereign AI is the government's big bet on promisingearly-stageAI companiestohelp themgrow,scaleand succeed from Britain, offering a range of backing to high-potential AI businesses that are starting out here in the UK.

It is aventure capital fund with the muscle of the state behind it - moving fast, backingambitionand cutting through the red tape that so often holds brilliant ideas back, sotheycan go on to succeedglobally.

Science and Technology Secretary Liz Kendall said:

Isomorphic Labs' ground-breaking work has the potential to reshapecompletely howmedicinesare discovered- cutting yearsoffdevelopmentandgiving real hopeto peopleliving with devastatingdiseases.This is AIat itsvery best- pushing the boundaries of innovation to improve people's lives.

Britain has a proud history of world-changing medical breakthroughs- frompenicillintoMRI scanners.Now in the AI era,we are backinga brilliant UKfirmworking on another huge jump forward in science to the benefit ofpeopleacross the country and around the world.

Isomorphic'swork builds on the breakthrough success of AlphaFold: the AI model developed by DeepMind that sent shockwaves through the world of science through its ability toaccurately predict the structures of proteins- which are the chemical building blocks of all life on Earth.

IsomorphicLabs is going beyondAlphaFold,developinga number ofproprietarybreakthroughAI models that together form its unified drug design engine, across multiple therapeutic areas and drug modalities.

This backing brings the number of startups receiving equity investment from Sovereign AI to 3since it launched, and the overall number of startups receiving Sovereign AI backing-including support accessing compute- to 9.

Sovereign AIHead of VenturesJosephine Kant said:

Isomorphic is one of the most consequential companies being built anywhere in the world today, andit'sbeing built in Britain.Sovereign AIexists to invest in the companies that will shape what this country becomes next.Sir DemisHassabis, MaxJaderberg, and theteamthey have builtdeservea country willing to match their ambition with its own, and we intend to make sure it does.

AI is the defining technology of our era. For Britain toshapeits ownfuturein the years ahead, the UK needs tostrong,homegrown AI capability.That means backing thevery best AI innovators,foundersand entrepreneurs to bring their ideas to lifehere - and growandsucceedfromtheUK.Withthe third largest AI market in the world and more AI startups than anywhere else in Europe, the UK is starting from a position ofstrengthbut weknowwe need to go further and faster. Sovereign AI is the government doing exactly that: making sure the next wave of AI breakthroughs are built inBritain so the benefits - jobs,growthand innovation - remain on our shores.

All ofthe companies Sovereign AI supports have a meaningful presence here in theUK, andare set to create jobs and contribute to the economy here.

ENDS

Notes to editors:

* The Fund will invest directly in promising UK AI companies to help them scale in the UK. Our investments will be focused on companies at the early and growth-stage. * Typical equity investments will be worth around £1-10 million, though every company's circumstances will be different. * Like most venture capitalfundswe do not comment on specific investment figures as they are commercially sensitive.

DSIT media enquiries

Emailpress@dsit.gov.uk

Monday to Friday, 8:30am to 6pm 020 7215 3000

Disclaimer: Curated by HT Syndication.